Replies to post #109360 on Biotech Values

[biomaven0]

If REGN is smart, they would undercut Lucentis a bit.

If NICE was trying to cut costs optimally, using Avastin in both eyes would be smarter than Lucentis in one eye. But Lucentis in one eye is better than nothing at all - at least the patient should still be able to read.

Peter